Source-monitoring task for French-speaking individuals with schizophrenia
Official title: Development of a Source-monitoring Task in French Adapted to Neuroimaging Protocols
Run by Hôpital le Vinatier · NCT04237155 · Data updated 2026-11-12
A French-language source-monitoring task is being tested to measure how people remember where information came from, including healthy adults and those with schizophrenia.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 45 Years |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | Hôpital le Vinatier Academic / other |
| Locations | 1 site (Bron) |
| Status | Recruiting |
| Started | February 7, 2020 |
| Main results expected | February 1, 2027 |
| Study ends | February 1, 2027 |
| Registry record updated | June 11, 2026 |
| Trial ID | NCT04237155 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18-45 who are native French speakers, with or without schizophrenia, and who can provide informed consent.
✕Probably not a fit
Individuals outside the age range, non-French speakers, or those unable to consent or meet the DSM-5 criteria may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This project aims to create a source-monitoring task that works with neuroimaging and is suitable for French speakers. The work consists of validating verbal materials and then testing the task in two steps. Interventions involve questionnaires and cognitive tests, with participants including adults 18-45 who are native French speakers. The study compares healthy controls to individuals with schizophrenia, following DSM-5 criteria.
Why it matters
Potential benefit: If successful, the task could provide a reliable way to study source memory in French-speaking clinical and healthy populations, potentially informing future research and therapies.
How similar studies have gone: Previous research has shown that task-based methods can measure source-monitoring, though adapting them for French-speaking populations and neuroimaging is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Men and Women aged between 18 and 45 * Having given their written informed consent * Native French speakers * Normal or corrected-to-normal vision * Education level greater than or equal to 8 (in years) * For the healthy control group, no history of previous diagnosed psychiatric disorders (according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders - DSM5), absence of first-degree relatives diagnosed with spectrum disorder schizophrenia and bipolar disorder (DSM). * For the schizophrenia patients group, meeting the DSM5 criteria for schizophrenia. Exclusion Criteria: * Do not consent to be included in the study * History of hearing impairments * People who cannot read * Presence of neurological or somatic diseases * Being under tutorship or curatorship
Where it's running
-
Centre Hospitalier le Vinatier
Bron, France Recruiting
Study contacts
- Study coordinator: Lydie Sartelet
- Email: lydie.sartelet@ch-le-vinatier.fr
- Phone: 0437915531
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using Lumateperone to improve motivation in patients with schizophrenia and psychosis
This study is testing if Lumateperone can help people with schizophrenia or schizoaffective disorders feel more motivated and less apathetic.
-
Examining the effects of combined therapy for schizophrenia
This study is testing whether combining two therapies, one for managing thoughts and another for improving cognitive skills, can help people with schizophrenia do better in their daily lives compared to using just one of the therapies.
-
XEP527 in stable schizophrenia: safety and how it behaves in the body
This small, early-stage study tests the safety and how XEP527 behaves in people with stable schizophrenia who are on a single antipsychotic.
-
Theta-Burst Transcranial Magnetic Stimulation for Treatment-Resistant Auditory Hallucinations
This study tests whether theta-burst transcranial magnetic stimulation can lessen persistent auditory verbal hallucinations in adults with schizophrenia-spectrum or psychotic disorders who have not responded to antipsychotic meds.
-
Quality of life and safety in quetiapine use for schizophrenia or bipolar disorder
This study looks at how patients with schizophrenia or bipolar disorder feel and stay safe when treated with quetiapine alone or with other antipsychotics.
-
Neuronavigated rTMS for treatment-resistant auditory hallucinations
We are testing whether personalized neuronavigated inhibitory rTMS can reduce persistent auditory verbal hallucinations in adults who don’t respond to medication.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.